Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Vandana Singh

4606 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • Movers
  • News
  • Trading Ideas

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge

By Vandana Singh
April 4, 2:32 PM
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

ABUS

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Movers
  • Reiteration
  • Trading Ideas

MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate

By Vandana Singh
April 4, 2:15 PM
Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). Safety and preliminary efficacy data anticipated by May 31. JMP Securities notes enhanced safety profile with new dosing regimen.

MGNX

Read More
1 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • Movers
  • News

Why Is Novartis Stock Trading Higher On Thursday?

By Vandana Singh
April 4, 2:09 PM
Novartis to file Pluvicto pre-taxane label expansion in 2H 2024 based on Phase 3 PSMAfore study data. Updated overall survival results show HR<1.0 in ITT population. rPFS consistent. Safety profile remains stable.

NVS

Read More
2 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Movers
  • News
  • Trading Ideas

Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus

By Vandana Singh
April 4, 1:54 PM
STAAR Surgical reports Q1 2024 net sales surpassing $77 million, with U.S. ICL sales hitting $5 million, the highest since FDA approval in 2022. CEO anticipates fiscal 2024 sales expected at the higher end of $335-340 million outlook.

STAA

Read More
2 minute read
  • Earnings
  • FDA
  • General
  • Guidance
  • Health Care
  • Movers
  • News

Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars

By Vandana Singh
April 4, 12:53 PM
FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens treatment options. Sales slightly below consensus, but pro forma basis sees growth.

ANGO

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

CureVac, GS Partner Release Data On Influenza Vaccine Study

By Vandana Singh
April 4, 12:18 PM
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A strains prompt further optimization for influenza B strains.

BNTX

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data

By Vandana Singh
April 4, 10:38 AM
eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a potential candidate for ER+ breast cancer trials.

EFTR

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

After Brain Cancer Data, Candel Therapeutics’ Shares Good News From Pancreatic Cancer Study

By Vandana Singh
April 4, 10:24 AM
Candel Therapeutics updates phase 2 trial results for CAN-2409 and valacyclovir in pancreatic cancer treatment, revealing prolonged survival rates up to 28.8 months versus standard therapy's 12.5 months.

CADL

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

In Heart Burn Drug Zantac’s Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster

By Vandana Singh
April 4, 9:16 AM
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed.

GSK

Read More
1 minute read
  • Exclusives
  • General
  • Market-Moving Exclusives
  • News
  • Real Estate
  • Tech

EXCLUSIVE: AI-Powered Real Estate Platform Janover Reports 73% Increase In Organic Website Traffic for 2023

By Vandana Singh
April 4, 8:02 AM
Janover sees a 73% surge in organic website traffic, driving loan applications and lender engagement. Achieved over 100 million Google impressions in 2023, showcasing market resilience and business value.

JNVR

Posts pagination

Previous 1 … 44 45 46 … 461 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service